Neurocrine Biosciences Inc (NASDAQ:NBIX), a company specializing in neurology and endocrinology treatments, has reported an insider sale according to a recent SEC filing. The insider, Chief Commercial Officer Eric Benevich, sold 75,000 shares of the company on March 14, 2024.
The transaction was executed at an average price of $139.38 per share, resulting in a total sale amount of approximately $10,453,500. Following this transaction, the insider's stake in Neurocrine Biosciences Inc has decreased, reflecting a notable change in their holdings.
Over the past year, Eric Benevich has sold a total of 156,165 shares of Neurocrine Biosciences Inc and has not made any purchases of the stock. The company's insider transaction history over the past year shows a total of 73 insider sells and no insider buys.
Neurocrine Biosciences Inc, with a market cap of $13.848 billion, is trading at a price-earnings ratio of 57.48. This valuation is higher than the industry median of 22.61 but lower than the company's historical median price-earnings ratio.
As of the date of the insider sale, shares of Neurocrine Biosciences Inc were trading at $139.38, which is fairly valued according to the GuruFocus Value of $150.71. The price-to-GF-Value ratio stands at 0.92, indicating that the stock is fairly valued based on its GF Value.
The GF Value is determined by considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates provided by Morningstar analysts.
The insider trend image above provides a visual representation of the insider selling and buying activities over the past year.
The GF Value image above offers insight into the stock's valuation relative to its intrinsic value estimate.
For more detailed information on insider transactions and the company's financial performance, interested parties can refer to the SEC filing linked in the article.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
